ST LOUIS (MD Consult) - On October 16, 2010, ISTA Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Bromday (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. Bromday is a nonsteroidal antiinflammatory compound.

One-drop dosing with Bromday may begin 1 day before surgery, and may be administered thereafter on the day of surgery and continuing for the first 14 days after surgery.

The most commonly reported adverse reactions reported in patients using Bromday were abnormal sensation in the eye, conjunctival hyperemia, and eye irritation (including burning/stinging).

圣路易斯(MD Consult)——2010年10月16日，ISTA制药公司宣布，美国食品药品管理局(FDA)已批准浓度为0.09%的处方药Bromday滴眼液(溴芬酸滴眼液)、每天1次用于治疗白内障摘除术后的炎症和减轻眼部疼痛。Bromday是一种非甾体抗炎化合物。

Bromday使用者中最常报告的不良反应是眼部感觉异常、结膜充血和眼部刺激症状(包括灼烧感/针刺感)。